nach oben

Zeitschrift für Pneumologie

Erschienen in:

01.09.2011 | CME Weiterbildung · Zertifizierte Fortbildung

COPD

verfasst von: Dr. A.-R. Koczulla, T. Greulich, S. Schmid, K. Kenn, I. Heinzelmann, C. Vogelmeier

Erschienen in: Zeitschrift für Pneumologie | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die chronisch obstruktive Lungenerkrankung (COPD) ist gekennzeichnet durch eine nicht voll reversible und in der Regel voranschreitende Atemwegsobstruktion. Ursächlich ist eine Inflammationsreaktion der Lunge auf inhalative Noxen, wobei das Zigarettenrauchen in Mitteleuropa die Hauptursache darstellt. In zahlreichen Studien konnten signifikante Zusammenhänge zwischen einer reduzierten FEV₁ und extrapulmonalen Erkrankungen gefunden werden. Die Verbindung zwischen der COPD und den extrapulmonalen Manifestationen der Erkrankung scheint eine systemische Inflammationsreaktion zu sein, wobei die genauen pathogenetischen Mechanismen noch nicht bekannt sind. Auch diagnostische Scores wie der gut validierte BODE-Score, die nicht nur anhand der Lungenfunktion den Schweregrad der COPD festlegen, reflektieren das systemische Krankheitsverständnis. Das holistische COPD-Verständnis spiegelt sich auch in neuen systemischen therapeutischen Ansätzen wider.

Vogelmeier C, Koczulla R, Fehrenbach H, Bals R (2006) Pathogenesis of chronic obstructive pulmonary disease. Internist (Berl) 47:885–890, 892

Vogelmeier C, Buhl R, Criee CP et al (2007) Guidelines for the diagnosis and therapy of COPD issued by Deutsche Atemwegsliga and Deutsche Gesellschaft fur Pneumologie und Beatmungsmedizin. Pneumologie 61:e1–e40PubMedCrossRef

Rabe KF (2006) Guidelines for chronic obstructive pulmonary disease treatment and issues of implementation. Proc Am Thorac Soc 3:641–644PubMedCrossRef

Rabe KF, Hurd S, Anzueto A et al (2007) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176:532–555PubMedCrossRef

Jones PW, Harding G, Berry P et al (2009) Development and first validation of the COPD Assessment Test. Eur Respir J 34:648–654PubMedCrossRef

Jones PW, Brusselle G, Dal Negro RW et al (2011) Properties of the COPD Assessment Test (CAT) in a cross-sectional European study. Eur Respir J 38:29–35PubMedCrossRef

McDonald CF (2010) ACP Journal Club. An updated BODE index and a simplified ADO index predicted 3-year mortality in COPD better than the original BODE index. Ann Intern Med 152:JC1–J12PubMed

Puhan MA, Garcia-Aymerich J, Frey M et al (2009) Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 374:704–711PubMedCrossRef

Marin JM, Cote CG, Diaz O et al (2011) Prognostic assessment in COPD: health related quality of life and the BODE index. Respir Med 105:916–921PubMedCrossRef

10.

Sarir H, Mortaz E, Karimi K et al (2009) Cigarette smoke regulates the expression of TLR4 and IL-8 production by human macrophages. J Inflamm (Lond) 6:12

11.

Sarir H, Mortaz E, Janse WT et al (2010) IL-8 production by macrophages is synergistically enhanced when cigarette smoke is combined with TNF-alpha. Biochem Pharmacol 79:698–705PubMedCrossRef

12.

Sauleda J, Garcia-Palmer FJ, Gonzalez G et al (2000) The activity of cytochrome oxidase is increased in circulating lymphocytes of patients with chronic obstructive pulmonary disease, asthma, and chronic arthritis. Am J Respir Crit Care Med 161:32–35PubMed

13.

Kohnlein T, Welte T (2008) Alpha-1 antitrypsin deficiency: pathogenesis, clinical presentation, diagnosis, and treatment. Am J Med 121:3–9PubMedCrossRef

14.

Marquis K, Debigare R, Lacasse Y et al (2002) Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166:809–813PubMedCrossRef

15.

Swallow EB, Reyes D, Hopkinson NS et al (2007) Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax 62:115–120PubMedCrossRef

16.

Tockman MS, Anthonisen NR, Wright EC, Donithan MG (1987) Airways obstruction and the risk for lung cancer. Ann Intern Med 106:512–518PubMed

17.

Barbera JA, Peinado VI, Santos S (2003) Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 21:892–905PubMedCrossRef

18.

Rutten FH, Moons KG, Cramer MJ et al (2005) Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ 331:1379PubMedCrossRef

19.

Rutten FH, Cramer MJ, Lammers JW et al (2006) Heart failure and chronic obstructive pulmonary disease: An ignored combination? Eur J Heart Fail 8:706–711PubMedCrossRef

20.

Watz H, Waschki B, Magnussen H (2010) Emphysema, airflow obstruction, and left ventricular filling. N Engl J Med 362:1638–1639PubMedCrossRef

21.

Watz H, Waschki B, Meyer T et al (2010) Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest 138:32–38PubMedCrossRef

22.

Barr RG, Bluemke DA, Ahmed FS et al (2010) Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med 362:217–227PubMedCrossRef

23.

Sin DD, Man SF (2005) Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2:8–11PubMedCrossRef

24.

Chatila WM, Thomashow BM, Minai OA et al (2008) Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 5:549–555PubMedCrossRef

25.

Barr RG, Mesia-Vela S, Austin JH et al (2007) Impaired flow-mediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the Emphysema and Cancer Action Project (EMCAP) Study. Am J Respir Crit Care Med 176:1200–1207PubMedCrossRef

26.

Fadini GP, Schiavon M, Cantini M et al (2006) Circulating progenitor cells are reduced in patients with severe lung disease. Stem Cells 24:1806–1813PubMedCrossRef

27.

Handschin C, Spiegelman BM (2008) The role of exercise and PGC1alpha in inflammation and chronic disease. Nature 454:463–469PubMedCrossRef

28.

Jorgensen NR, Schwarz P (2008) Osteoporosis in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 14:122–127PubMedCrossRef

29.

Calverley P, Pauwels R, Vestbo J et al (2003) Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361:449–456PubMedCrossRef

30.

Jorgensen NR, Schwarz P, Holme I et al (2007) The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. Respir Med 101:177–185PubMedCrossRef

31.

Vrieze A, Greef MH de, Wijkstra PJ, Wempe JB (2007) Low bone mineral density in COPD patients related to worse lung function, low weight and decreased fat-free mass. Osteoporos Int 18:1197–1202PubMedCrossRef

32.

Carter JD, Patel S, Sultan FL et al (2008) The recognition and treatment of vertebral fractures in males with chronic obstructive pulmonary disease. Respir Med 102:1165–1172PubMedCrossRef

33.

Bolton CE, Ionescu AA, Shiels KM et al (2004) Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170:1286–1293PubMedCrossRef

34.

Lam J, Takeshita S, Barker JE et al (2000) TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106:1481–1488PubMedCrossRef

35.

Ebeling PR (2008) Clinical practice. Osteoporosis in men. N Engl J Med 358:1474–1482PubMedCrossRef

36.

John M, Lange A, Hoernig S et al (2006) Prevalence of anemia in chronic obstructive pulmonary disease: comparison to other chronic diseases. Int J Cardiol 111:365–370PubMedCrossRef

37.

Similowski T, Agusti A, MacNee W, Schonhofer B (2006) The potential impact of anaemia of chronic disease in COPD. Eur Respir J 27:390–396PubMedCrossRef

38.

Rana JS, Mittleman MA, Sheikh J et al (2004) Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care 27:2478–2484PubMedCrossRef

39.

Fletcher EC (1990) Chronic lung disease in the sleep apnea syndrome. Lung 168(Suppl):751–761PubMedCrossRef

40.

Alam I, Lewis K, Stephens JW, Baxter JN (2007) Obesity, metabolic syndrome and sleep apnoea: all pro-inflammatory states. Obes Rev 8:119–127PubMedCrossRef

41.

Carpagnano GE, Kharitonov SA, Resta O et al (2002) Increased 8-isoprostane and interleukin-6 in breath condensate of obstructive sleep apnea patients. Chest 122:1162–1167PubMedCrossRef

42.

Ryan S, Taylor CT, McNicholas WT (2009) Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome? Postgrad Med J 85:693–698PubMedCrossRef

43.

Kohler M, Ayers L, Pepperell JC et al (2009) Effects of continuous positive airway pressure on systemic inflammation in patients with moderate to severe obstructive sleep apnoea: a randomised controlled trial. Thorax 64:67–73PubMedCrossRef

44.

Constantinidis J, Ereliadis S, Angouridakis N et al (2008) Cytokine changes after surgical treatment of obstructive sleep apnoea syndrome. Eur Arch Otorhinolaryngol 265:1275–1279PubMedCrossRef

45.

Carpagnano GE, Kharitonov SA, Resta O et al (2003) 8-Isoprostane, a marker of oxidative stress, is increased in exhaled breath condensate of patients with obstructive sleep apnea after night and is reduced by continuous positive airway pressure therapy. Chest 124:1386–1392PubMedCrossRef

46.

Constantinidis J, Ereliadis S, Angouridakis N et al (2008) Cytokine changes after surgical treatment of obstructive sleep apnoea syndrome. Eur Arch Otorhinolaryngol 265:1275–1279PubMedCrossRef

47.

Yohannes AM, Willgoss TG, Baldwin RC, Connolly MJ (2010) Depression and anxiety in chronic heart failure and chronic obstructive pulmonary disease: prevalence, relevance, clinical implications and management principles. Int J Geriatr Psychiatry 25:1209–1221PubMedCrossRef

48.

Ebbert JO, Wyatt KD, Hays JT et al (2010) Varenicline for smoking cessation: efficacy, safety, and treatment recommendations. Patient Prefer Adherence 4:355–362PubMedCrossRef

49.

Vogelmeier C, Hederer B, Glaab T et al (2011) Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 364:1093–1103PubMedCrossRef

50.

Vogelmeier C, Ramos-Barbon D, Jack D et al (2010) Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res 11:135PubMedCrossRef

51.

(o A) (1997) Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study Group. Chest 112:1514–1521

52.

Taylor DR, Buick B, Kinney C et al (1985) The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. Am Rev Respir Dis 131:747–751PubMed

53.

Noord JA van, Aumann JL, Janssens E et al (2005) Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 26:214–222PubMedCrossRef

54.

Burge PS, Calverley PM, Jones PW et al (2000) Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320:1297–1303PubMedCrossRef

55.

Burge PS, Calverley PM, Jones PW et al (2003) Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax 58:654–658PubMedCrossRef

56.

Postma DS, Kerstjens HA (1999) Are inhaled glucocorticosteroids effective in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 160:S66–S71PubMed

57.

58.

Calverley PM, Anderson JA, Celli B et al (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356:775–789PubMedCrossRef

59.

Calverley PM, Boonsawat W, Cseke Z et al (2003) Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 22:912–919PubMedCrossRef

60.

Aaron SD, Vandemheen KL, Fergusson D et al (2007) Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 146:545–555PubMed

61.

Szafranski W, Cukier A, Ramirez A et al (2003) Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21:74–81PubMedCrossRef

62.

Grootendorst DC, Gauw SA, Benschop N et al (2003) Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD). Pulm Pharmacol Ther 16:341–347PubMedCrossRef

63.

Grootendorst DC, Gauw SA, Verhoosel RM et al (2007) Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 62:1081–1087PubMedCrossRef

64.

Young RP, Hopkins R, Eaton TE (2009) Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev 18:222–232PubMedCrossRef

65.

Garvey C, Fromer L, Saver DF, Yawn BP (2010) Pulmonary rehabilitation: an underutilized resource in primary COPD care. Phys Sportsmed 38:54–60PubMedCrossRef

66.

Schulze M, Song B, Gietzelt M et al (2010) Supporting rehabilitation training of COPD patients through multivariate sensor-based monitoring and autonomous control using a Bayesian network: prototype and results of a feasibility study. Inform Health Soc Care 35:144–156PubMedCrossRef

67.

De Backer LA, Ides K, Daems D et al (2010) Pulmonary rehabilitation and non-invasive ventilation in COPD. Acta Clin Belg 65:330–335

68.

Ninot G, Moullec G, Picot MC et al (2010) Cost-saving effect of supervised exercise associated to COPD self-management education program. Respir Med 105:377–385PubMedCrossRef

69.

Troosters T, Gosselink R, Janssens W, Decramer M (2010) Exercise training and pulmonary rehabilitation: new insights and remaining challenges. Eur Respir Rev 19:24–29PubMedCrossRef

70.

Nici L, Lareau S, ZuWallack R (2010) Pulmonary rehabilitation in the treatment of chronic obstructive pulmonary disease. Am Fam Physician 82:655–660PubMed

71.

Marciniuk DD, Brooks D, Butcher S et al (2010) Optimizing pulmonary rehabilitation in chronic obstructive pulmonary disease – practical issues: a Canadian Thoracic Society Clinical Practice Guideline. Can Respir J 17:159–168PubMed

72.

Troosters T, Probst VS, Crul T et al (2010) Resistance training prevents deterioration in quadriceps muscle function during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 181:1072–1077PubMedCrossRef

73.

Puhan MA, Scharplatz M, Troosters T, Steurer J (2005) Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality – a systematic review. Respir Res 6:54PubMedCrossRef

74.

Casaburi R, Kukafka D, Cooper CB et al (2005) Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 127:809–817PubMedCrossRef

75.

(o A) (2010) Preventing exacerbations in COPD. Drug Ther Bull 48:74–77

76.

Engel RM, Vemulpad S (2009) Progression to chronic obstructive pulmonary disease (COPD): Could it be prevented by manual therapy and exercise during the „at risk“ stage (stage 0)? Med Hypotheses 72:288–290PubMedCrossRef

77.

Koczulla AR et al. (2012) COPD and rehabilitation. In: Mooren FC, Skinner JS (Hrsg) Encyclopedia of exercise medicine in health and disease. Springer, Berlin Heidelberg New York Tokyo (im Druck)

78.

Halle M, Heitmann RH, Kenn K et al (2008) Evidence and technique for exercise training in patients with COPD. Pneumologie 62:209–221PubMedCrossRef

79.

(o A) American College of Sports Medicine Position Stand (1998) The recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness, and flexibility in healthy adults. Med Sci Sports Exerc 30:975–991

80.

The National Emphysema Treatment Trial Research Group (1999) Rationale and design of The National Emphysema Treatment Trial. A prospective randomized trial of lung volume reduction surgery. Chest 116:1750–1761CrossRef

81.

Sciurba FC, Ernst A, Herth FJ et al (2010) A randomized study of endobronchial valves for advanced emphysema. N Engl J Med 363:1233–1244PubMedCrossRef

82.

Strange C, Herth FJ, Kovitz KL et al (2007) Design of the Endobronchial Valve for Emphysema Palliation Trial (VENT): a non-surgical method of lung volume reduction. BMC Pulm Med 7:10PubMedCrossRef

83.

Cassivi SD, Meyers BF, Battafarano RJ et al (2002) Thirteen-year experience in lung transplantation for emphysema. Ann Thorac Surg 74:1663–1669PubMedCrossRef

Titel: COPD
verfasst von: Dr. A.-R. Koczulla
T. Greulich
S. Schmid
K. Kenn
I. Heinzelmann
C. Vogelmeier
Publikationsdatum: 01.09.2011
Verlag: Springer-Verlag
Erschienen in: Zeitschrift für Pneumologie / Ausgabe 5/2011
Print ISSN: 2731-7404
Elektronische ISSN: 2731-7412
DOI: https://doi.org/10.1007/s10405-011-0515-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

COPD

Zusammenfassung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2011

Transplantationsassoziierte Pathologie der Lunge

Pathologie und Diagnose der Lungentuberkulose sowie nichttuberkulöser Mykobakterien

Lungentumor mit arteriellem Verschluss

Pathologie primär pulmonaler Lymphome

Zytologie in der Pneumologie

Pulmonale Granulomatosen

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin